Media Outlets Highlight New JAMA Study Led by Dr. Roberto Caricchio Examining Canakinumab vs. Placebo on Survival without Mechanical Ventilation in Patients Hospitalized with Severe COVID-19

Media outlets, including Healio Rheumatology, HCPLive and Daily Mail, highlighted a new study published in JAMA examining the effect of the IL-1 inhibitor canakinumab (Ilaris) vs. placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. The study’s corresponding author is Roberto Caricchio, MD, FACR, Chief of the Section of Rheumatology, Professor of Medicine and Professor of Microbiology and Immunology at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lupus Program at Temple University Hospital.